4.1 Failure to induce global/clinical remission |
11 |
1968 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.94 [0.86, 1.02] |
4.1.1 Asacol comparator |
6 |
720 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.94 [0.85, 1.04] |
4.1.2 Claversal comparator |
2 |
530 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.95 [0.78, 1.17] |
4.1.3 Salofalk comparator |
2 |
491 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.92 [0.72, 1.18] |
4.1.4 Pentasa comparator |
1 |
227 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.90 [0.74, 1.10] |
4.2 Failure to induce global/clinical remission (sensitivity analysis) |
9 |
1681 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.95 [0.87, 1.04] |
4.2.1 Asacol comparator |
5 |
660 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.86, 1.07] |
4.2.2 Claversal comparator |
2 |
530 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.95 [0.78, 1.17] |
4.2.3 Salofalk comparator |
2 |
491 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.92 [0.72, 1.18] |
4.3 Failure to induce global/clinical improvement (including remission) |
8 |
1647 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.89 [0.77, 1.01] |
4.3.1 Asacol comparator |
3 |
399 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.90 [0.73, 1.11] |
4.3.2 Claversal comparator |
2 |
530 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.86 [0.67, 1.10] |
4.3.3 Salofalk comparator |
2 |
491 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.74, 1.36] |
4.3.4 Pentasa comparator |
1 |
227 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.70 [0.45, 1.08] |
4.4 Failure to induce global/clinical improvement (sensitivity analysis) |
7 |
1420 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.91 [0.79, 1.05] |
4.4.1 Asacol comparator |
3 |
399 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.90 [0.73, 1.11] |
4.4.2 Claversal comparator |
2 |
530 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.86 [0.67, 1.10] |
4.4.3 Salofalk comparator |
2 |
491 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.74, 1.36] |
4.5 Adverse events |
9 |
1576 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.92, 1.12] |
4.5.1 Asacol comparator |
5 |
556 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.91 [0.80, 1.03] |
4.5.2 Claversal comparator |
2 |
530 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.30 [1.01, 1.66] |
4.5.3 Salofalk comparator |
2 |
490 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.81, 1.20] |
4.6 Serious adverse events |
4 |
677 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.59 [0.22, 1.56] |
4.6.1 Asacol comparator |
2 |
277 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.33 [0.05, 2.11] |
4.6.2 Claversal comparator |
1 |
168 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.68 [0.16, 2.95] |
4.6.3 Salofalk comparator |
1 |
232 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.14, 6.74] |
4.7 Withdrawals due to adverse events |
9 |
1489 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.94 [0.57, 1.54] |
4.7.1 Asacol comparator |
6 |
726 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.48 [0.22, 1.04] |
4.7.2 Claversal comparator |
2 |
530 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.48 [0.70, 3.14] |
4.7.3 Salofalk comparator |
1 |
233 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.90 [0.44, 34.35] |
4.8 Exclusions and withdrawals after study entry |
9 |
1574 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.80, 1.22] |
4.8.1 Asacol comparator |
5 |
553 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.91 [0.67, 1.24] |
4.8.2 Claversal comparator |
2 |
530 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.10 [0.74, 1.63] |
4.8.3 Salofalk comparator |
2 |
491 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.67, 1.51] |